Switching CGRP(r) MoAbs in migraine: what evidence?
{{output}}
Introduction: Approximately 50% of patients that receive a CGRP(r) MoAb for the preventative treatment of migraine are expected to discontinue therapy. For patients that discontinue CGRP(r) MoAb therapy, few clinical options are ... ...
